Gilead Wins Legal Battle on Biktarvy Pricing | Durham News

Gilead Sciences just won a major legal battle that could reshape U.S. drug pricing, as a federal appeals court blocked the import of cheaper foreign versions of its top HIV drug Biktarvy — a move that protects Gilead’s dominant revenue stream and forces insurers to pay full price. The court ruled the imported drugs weren’t equivalent due to different quality controls, siding with Gilead on trademark and unfair competition claims. This decision bolsters Gilead’s financial outlook, with HIV sales hitting $5.7 billion in Q2 and a raised full-year forecast, while also clearing up another legal hurdle in California. Investors now eye upcoming FDA approvals, especially an HIV combo pill due by August 27th, as key growth catalysts. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/16a8639a781c25ce